Insurance companies must not be a roadblock to SMA patients accessing lifesaving treatments. Anthem insurance is already one such roadblock.
Anthem seeks to limit access to Spinraza to only Type 1 patients with 2 SMN2 copies. Anthem is altering Spinraza’s label, which has already been approved by the FDA, by restricting who it is provided to, and decreasing the treatment schedule. This is a heinous maneuver that could cost lives!
Spinal Muscular Atrophy is a degenerative, terminal disease for which Spinraza is the only FDA-approved treatment. The FDA recently approved Spinraza for EVERY PATIENT THAT SUFFERS FROM SMA – no restrictions to type, SMN2 number, or age. Insurance companies should not be allowed to withhold or deny this lifesaving treatment.